Overview
Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer
Status:
Unknown status
Unknown status
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
To determine the overall objective response rate of pegylated liposomal doxorubicin （Lipo-Dox）combined with cyclophosphamide/5-FU as second-line treatment in patients with metastatic breast cancer.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
TTY BiopharmTreatments:
Cyclophosphamide
Doxorubicin
Fluorouracil
Liposomal doxorubicin
Criteria
Inclusion Criteria:- histologically proved breast cancer with metastatic disease
Exclusion Criteria:
- life expectancy less than 3 months.